Management of neovascular age-related macular degeneration: Current state-of-the-art care for optimizing visual outcomes and therapies in development

Aniruddha Agarwal, William R. Rhoades, Mostafa Hanout, Mohamed Kamel Soliman, Salman Sarwar, Mohammad Ali Sadiq, Yasir Jamal Sepah, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Contemporary management of neovascular age-related macular degeneration (AMD) has evolved significantly over the last few years. The goal of treatment is shifting from merely salvaging vision to maintaining a high quality of life. There have been significant breakthroughs in the identification of viable drug targets and gene therapies. Imaging tools with near-histological precision have enhanced our knowledge about pathophysiological mechanisms that play a role in vision loss due to AMD. Visual, social, and vocational rehabilitation are all important treatment goals. In this review, evidence from landmark clinical trials is summarized to elucidate the optimum modern-day management of neovascular AMD. Therapeutic strategies currently under development, such as gene therapy and personalized medicine, are also described.

Original languageEnglish (US)
Pages (from-to)1001-1015
Number of pages15
JournalClinical Ophthalmology
Volume9
DOIs
StatePublished - Jun 5 2015

Fingerprint

Macular Degeneration
Genetic Therapy
Vocational Rehabilitation
Precision Medicine
Therapeutics
Quality of Life
Clinical Trials
Drug Therapy

Keywords

  • AMD
  • Choroidal neovascular membrane
  • Gene therapy
  • Low-vision rehabilitation
  • Neovascular AMD
  • Pharmacogenomics
  • VEGF

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Management of neovascular age-related macular degeneration : Current state-of-the-art care for optimizing visual outcomes and therapies in development. / Agarwal, Aniruddha; Rhoades, William R.; Hanout, Mostafa; Soliman, Mohamed Kamel; Sarwar, Salman; Sadiq, Mohammad Ali; Sepah, Yasir Jamal; Do, Diana V.; Nguyen, Quan Dong.

In: Clinical Ophthalmology, Vol. 9, 05.06.2015, p. 1001-1015.

Research output: Contribution to journalArticle

Agarwal, Aniruddha ; Rhoades, William R. ; Hanout, Mostafa ; Soliman, Mohamed Kamel ; Sarwar, Salman ; Sadiq, Mohammad Ali ; Sepah, Yasir Jamal ; Do, Diana V. ; Nguyen, Quan Dong. / Management of neovascular age-related macular degeneration : Current state-of-the-art care for optimizing visual outcomes and therapies in development. In: Clinical Ophthalmology. 2015 ; Vol. 9. pp. 1001-1015.
@article{3f4e880213b64600944f520349037883,
title = "Management of neovascular age-related macular degeneration: Current state-of-the-art care for optimizing visual outcomes and therapies in development",
abstract = "Contemporary management of neovascular age-related macular degeneration (AMD) has evolved significantly over the last few years. The goal of treatment is shifting from merely salvaging vision to maintaining a high quality of life. There have been significant breakthroughs in the identification of viable drug targets and gene therapies. Imaging tools with near-histological precision have enhanced our knowledge about pathophysiological mechanisms that play a role in vision loss due to AMD. Visual, social, and vocational rehabilitation are all important treatment goals. In this review, evidence from landmark clinical trials is summarized to elucidate the optimum modern-day management of neovascular AMD. Therapeutic strategies currently under development, such as gene therapy and personalized medicine, are also described.",
keywords = "AMD, Choroidal neovascular membrane, Gene therapy, Low-vision rehabilitation, Neovascular AMD, Pharmacogenomics, VEGF",
author = "Aniruddha Agarwal and Rhoades, {William R.} and Mostafa Hanout and Soliman, {Mohamed Kamel} and Salman Sarwar and Sadiq, {Mohammad Ali} and Sepah, {Yasir Jamal} and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2015",
month = "6",
day = "5",
doi = "10.2147/OPTH.S74959",
language = "English (US)",
volume = "9",
pages = "1001--1015",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Management of neovascular age-related macular degeneration

T2 - Current state-of-the-art care for optimizing visual outcomes and therapies in development

AU - Agarwal, Aniruddha

AU - Rhoades, William R.

AU - Hanout, Mostafa

AU - Soliman, Mohamed Kamel

AU - Sarwar, Salman

AU - Sadiq, Mohammad Ali

AU - Sepah, Yasir Jamal

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2015/6/5

Y1 - 2015/6/5

N2 - Contemporary management of neovascular age-related macular degeneration (AMD) has evolved significantly over the last few years. The goal of treatment is shifting from merely salvaging vision to maintaining a high quality of life. There have been significant breakthroughs in the identification of viable drug targets and gene therapies. Imaging tools with near-histological precision have enhanced our knowledge about pathophysiological mechanisms that play a role in vision loss due to AMD. Visual, social, and vocational rehabilitation are all important treatment goals. In this review, evidence from landmark clinical trials is summarized to elucidate the optimum modern-day management of neovascular AMD. Therapeutic strategies currently under development, such as gene therapy and personalized medicine, are also described.

AB - Contemporary management of neovascular age-related macular degeneration (AMD) has evolved significantly over the last few years. The goal of treatment is shifting from merely salvaging vision to maintaining a high quality of life. There have been significant breakthroughs in the identification of viable drug targets and gene therapies. Imaging tools with near-histological precision have enhanced our knowledge about pathophysiological mechanisms that play a role in vision loss due to AMD. Visual, social, and vocational rehabilitation are all important treatment goals. In this review, evidence from landmark clinical trials is summarized to elucidate the optimum modern-day management of neovascular AMD. Therapeutic strategies currently under development, such as gene therapy and personalized medicine, are also described.

KW - AMD

KW - Choroidal neovascular membrane

KW - Gene therapy

KW - Low-vision rehabilitation

KW - Neovascular AMD

KW - Pharmacogenomics

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84934783509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934783509&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S74959

DO - 10.2147/OPTH.S74959

M3 - Article

C2 - 26089632

AN - SCOPUS:84934783509

VL - 9

SP - 1001

EP - 1015

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -